Antiviral Briefs

December 2008
AIDS Patient Care & STDs;Dec2008, Vol. 22 Issue 12, p1021
Academic Journal
The article offers news briefs related to HIV antiviral agents in the U.S. The World Health Organization (WHO) advises doctors to start early the treatment of HIV-infected babies to eliminate the bad effects of the treatment. Quest Clinical researchers reveal that etravirine does not contain hepatotoxicity and does not cause serum alanin transaminase levels (ALT). The Food and Drug Administration (FDA) has approved the commercialization of Prezista for the treatment of HIV-1 infection.


Related Articles

  • FDA Actions.  // Clinical Cardiology Alert;Dec2009 Pharmacology Watch, p2 

    The article focuses on the approval by the U.S. Food and Drug Administration of the emergency use of antiviral peramivir to treat 2009 H1N1 influenza in hospitalized patients. The author notes that the drug is not yet approved for use in the country but was authorized due to a request from...

  • Pansinusitis in an HIV-infected patient due to Scedosporium apiospermum (Pseudallescheria boydii complex). Kenyon, C.; Mendelson, M.; Lubbe, D.; Khoury, B.; Vismer, H.; Hoffman, R. // Southern African Journal of Epidemiology & Infection;2011, Vol. 26 Issue 2, p88 

    Pseudallescheria boydii is a very rare cause of sinusitis but an increasingly recognised infection among HIV-infected patients. Its correct identification is vital as voriconazole, which has good in vitro activity against the fungus, has important interactions with antiretroviral drugs. We...

  • Emtriva Receives FDA Nod.  // Guide;Nov2003, Vol. 23 Issue 11, p46 

    Reports on the U.S. Food and Drug Administration's approval of Emtriva for use in combination with other antiretroviral agents in the treatment of HIV infection. Assessment of nucleoside reverse transcriptase inhibitor Emtriva by genotypic or phenotypic testing; Increase in mean baseline CD4...

  • FDA Approves Viread for HIV-1 Infection.  // FDA Consumer;Jan/Feb2002, Vol. 36 Issue 1, p5 

    Reports that the United States Food and Drug Administration has approved Viread, an antiviral drug for the treatment of HIV-1 infection in combination with other antiretroviral medicines. Most frequently reported adverse events among patients in the clinical trials; Marketer of Viread.

  • Prodrug of tenofovir diphosphate approved for combination HIV therapy.  // American Journal of Health-System Pharmacy;1/1/2002, Vol. 59 Issue 1, p18 

    Reports on United States Food and Drug Administration's market approval of tenofovir disopropxil fumarate for the treatment of HIV. Drug effectiveness; Findings of clinical trials; Drug bioavailability; Dosage recommendation; Adverse effects of the drug.

  • US Okays More Potent HIV Drug Formulation.  // Clinical Infectious Diseases;2/15/2005, Vol. 40 Issue 4, preceding p1 

    This article reports that the U.S. Food and Drug Administration has granted approval to a more potent formulation of Roche AG's HIV drug invirase, meaning that patients will not need to take as many of the pills.

  • Antiviral Briefs.  // AIDS Patient Care & STDs;Jan2008, Vol. 22 Issue 1, p85 

    The article offers news briefs related to antiviral agents. The U.S. Department of Health and Human Services (DHHS) has issued updated guidelines for the use of antiretroviral agents in teens and adults infected with human immunodeficiency virus type 1 (HIV-1). The U.S. Food and Drug...

  • Incorporating Drug-Resistance Measurements into the Clinical Management of HIV-1 Infection. Zolopa, Andrew R. // Journal of Infectious Diseases;9/16/2006, Vol. 194, pS59 

    Testing for resistance to antiretrovirals is considered to be standard of care and is widely used in the management of human immunodeficiency virus (HIV)-infected persons. Despite the widespread use of resistance testing, the clinician still faces a number of challenges when applying these...

  • Highly Active Antiretroviral Therapy: Current State of the Art, New Agents and Their Pharmacological Interactions Useful for Improving Therapeutic Outcome. Barbaro, Giuseppe; Scozzafava, Andrea; Mastrolorenzo, Antonio; Supuran, Claudiu T. // Current Pharmaceutical Design;May2005, Vol. 11 Issue 14, p1805 

    Highly active antiretroviral therapy (HAART) dramatically changed the course of HIV infection. Currently, this therapy involves the use of agents from at least two distinct classes of antivirals: a protease inhibitor (PI) in combination with two nucleoside/nucleotide reverse transcriptase...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics